Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Project cooperationUpdated on 9 April 2026

ASPER2

Filip Rázga

CEO at Selecta Biotech SE

Bratislava, Slovakia

About

ASPER2 is a therapeutic oligonucleotide based on the ESiNAR-X platform, intended for patients with gradually progressive chronic kidney disease accompanied by renal fibrosis.

Status: Finished pre-clinical validation

We are seeking investments and partnerships to support the execution of clinical trials.

Similar opportunities